Scarica l'app Stockscreener
3.98
2.84%
0.11
Dopo l'orario di chiusura:
4.05
0.07
+1.76%
Precedente Chiudi:
$3.87
Aprire:
$3.93
Volume 24 ore:
1.72M
Relative Volume:
1.14
Capitalizzazione di mercato:
$453.90M
Reddito:
$884.00K
Utile/perdita netta:
$-103.64M
Rapporto P/E:
-2.8543
EPS:
-1.3944
Flusso di cassa netto:
$-95.45M
1 W Prestazione:
+3.38%
1M Prestazione:
-15.50%
6M Prestazione:
+90.43%
1 anno Prestazione:
+58.57%
Intervallo 1D:
$3.905
$4.105
Intervallo di 1 settimana:
$3.585
$4.105
Portata 52W:
$1.955
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
Nome
Perspective Therapeutics Inc
Settore
Industria
Telefono
509-375-1202
Indirizzo
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.98 | 441.36M | 884.00K | -103.64M | -95.45M | -1.3944 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-19 | Iniziato | Piper Sandler | Overweight |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-10-10 | Iniziato | BTIG Research | Buy |
| 2025-03-13 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-11-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-01 | Iniziato | Wedbush | Outperform |
| 2024-09-25 | Iniziato | Truist | Buy |
| 2024-07-25 | Iniziato | BofA Securities | Buy |
| 2024-05-09 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Perspective Therapeutics Inc Borsa (CATX) Ultime notizie
A Quick Look at Today's Ratings for Perspective Therapeutics(CATX.US), With a Forecast Between $8 to $15 - Moomoo
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6 - Moomoo
Piper Sandler Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Perspective Therapeutics Presents Positive Clinical Data for [212Pb] Radiopharmaceuticals in Melanoma, Neuroendocrine, and Solid Tumors at ASCO 2026 - Minichart
CATX Technical Analysis | Trend, Signals & Chart Patterns | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
Perspective Therapeutics (NYSE: CATX) highlights new 212Pb trial data at 2026 ASCO - Stock Titan
Perspective Therapeutics, Inc. Reports Positive Updates on Clinical Programs at ASCO 2026, Highlighting Efficacy and Safety of [212Pb]VMT-α-NET, [212Pb]VMT01, and [212Pb]PSV359 - Quiver Quantitative
Early melanoma trial sees tumor responses in hard-to-treat patients - Stock Titan
UBS Maintains Perspective Therapeutics (CATX) Buy Recommendation - MSN
Perspective Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Earnings Preview: CATX to Report Financial Results Post-market on May 11 - Moomoo
CATX: VMT-α-NET shows high efficacy and safety, with phase III readiness and broad pipeline progress - TradingView
CATX News | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
Perspective Therapeutics doses first patients in two trial cohorts By Investing.com - Investing.com Australia
Perspective Therapeutics doses first patients in two trial cohorts - Investing.com UK
Perspective Therapeutics (CATX) Begins Patient Dosing in New Cli - GuruFocus
Perspective Therapeutics Doses First Patients for New Cohorts of Two Phase 1/2a Studies in Tumors - marketscreener.com
Perspective Therapeutics, Inc. Initiates Patient Dosing in Phase 1/2a Studies for [212Pb]VMT-α-NET and [212Pb]PSV359 in Neuroendocrine and Solid Tumors - Quiver Quantitative
Two cancer radiopharmaceuticals start dosing patients in early trials - Stock Titan
CATX Should I Buy - Intellectia AI
Analysts Are Bullish on These Healthcare Stocks: SI-Bone (SIBN), Perspective Therapeutics (CATX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Perspective Therapeutics (CATX) - The Globe and Mail
CATX Stock Price, Quote & Chart | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
Morgan Stanley lists shared 2.6% stake in Perspective Therapeutics (CATX) - Stock Titan
RBC Capital reiterates Outperform on Perspective Therapeutics stock By Investing.com - Investing.com Nigeria
RBC Capital reiterates Outperform on Perspective Therapeutics stock - Investing.com
MSN Money - MSN
Working capital per share of Perspective Therapeutics, Inc. – FWB:AAJ0 - TradingView
Perspective Therapeutics earnings beat by $0.05, revenue fell short of estimates - Investing.com Canada
Perspective Therapeutics (NYSEARCA:CATX) Posts Mixed Q1 2026 Results, EPS Beat and Revenue Miss - ChartMill
Perspective Therapeutics 1Q Loss/Shr 25c >CATX - Moomoo
Is Perspective Therapeutics (CATX) Attractively Valued After Q1 - GuruFocus
Perspective Therapeutics: Q1 Earnings Snapshot - WKYC
Perspective Therapeutics Highlights Q1 Progress and Strengthened Finances - TipRanks
Perspective Therapeutics Q1 net loss widens as grant revenue drops - TradingView
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results - The Manila Times
[10-Q] Perspective Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Perspective Therapeutics (NYSE: CATX) posts Q1 loss, cash runway to late 2027 - Stock Titan
Perspective Therapeutics: $271M cash to advance 3 cancer trials - Stock Titan
Number of shareholders of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
Number of shareholders of Perspective Therapeutics, Inc. – DUS:AAJ0 - TradingView
Perspective Therapeutics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Transcript : Perspective Therapeutics, Inc.Shareholder/Analyst Call - marketscreener.com
JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $18 - Moomoo
RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX) - The Globe and Mail
Perspective Therapeutics (CATX) Receives a Buy from Piper Sandler - The Globe and Mail
RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $14 - 富途牛牛
Wedbush Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Perspective Therapeutics Advances 212Pb Radioligand Therapy for Targeted Oncology with Regional Manufacturing and Theranostic Approach 1245 - Minichart
Perspective Therapeutics Inc Azioni (CATX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.22%
1.41%
Capitalizzazione:
|
Volume (24 ore):